|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for NT5E |
 Gene summary |
| Basic gene Info. | Gene symbol | NT5E |
| Gene name | 5'-nucleotidase, ecto (CD73) | |
| Synonyms | CALJA|CD73|E5NT|NT|NT5|NTE|eN|eNT | |
| Cytomap | UCSC genome browser: 6q14-q21 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001204813.1, NM_002526.3, | |
| Description | 5'-NT5'-nucleotidasePurine 5-Prime-Nucleotidaseecto-5'-nucleotidase | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 129190 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000135318 | ||
| HPRD : 00552 | ||
| Vega : OTTHUMG00000015139 | ||
| Protein | UniProt: P21589 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_NT5E | |
| BioGPS: 4907 | ||
| Pathway | NCI Pathway Interaction Database: NT5E | |
| KEGG: NT5E | ||
| REACTOME: NT5E | ||
| Pathway Commons: NT5E | ||
| Context | iHOP: NT5E | |
| ligand binding site mutation search in PubMed: NT5E | ||
| UCL Cancer Institute: NT5E | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for NT5E |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | H220 | S221L | BLCA | 1 | H118 | E119Q | BRCA | 1 | F417 | P416T | LUAD | 1 | G298 | V300I | OV | 1 | D237 | G235S | SKCM | 1 | K214 | K214T | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for NT5E |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | H220 | S221L | 0.3867266 | H118 | E119Q | -0.98169281 | F417 | P416T | -0.94090144 | D237 | G235S | -0.79326283 | K214 | K214T | -0.54157622 | G298 | V300I | -0.23325423 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for NT5E from PDB |
| Top |
| Differential gene expression and gene-gene network for NT5E |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for NT5E |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C1859372 | Calcification of Joints and Arteries | 2 | Biomarker, GeneticVariation |
| umls:C0023893 | Liver Cirrhosis, Experimental | 1 | Biomarker |
| umls:C0038356 | Stomach Neoplasms | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for NT5E |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Approved|investigational | DB00806 | Pentoxifylline | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of NT5E go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | CA | CALCIUM(2+) | 4h1y | P | D237 G298 | CA | CALCIUM(2+) | 4h2b | A | D237 G298 | CA | CALCIUM(2+) | 4h2i | A | D237 G298 | 0YQ | 2,2'-[(2-{[2-({[(2S,3S,4R,5R)-5-(2,4-DIOXO-3,4- DIHYDROPYRIMIDIN-1(2H)-YL)-3,4- DIHYDROXYTETRAHYDROFURAN-2-YL]CARBONYL}AMINO) ETHYL]AMINO}-2-OXOETHYL)IMINO]DIACETIC ACID (NON- PREFERRED NAME) | 4h1y | P | F417 | 0XE | BAICALIN | 5,6-DIHYDROXY-4-OXO-2-PHENYL-4H-CHROMEN-7-YL BETA-D- GLUCOPYRANOSIDURONIC ACID | 4h2b | A | F417 | ADN | ADENOSINE | 4h2f | A | F417 | ADN | ADENOSINE | 4h2g | A | F417 | A12 | ADENOSINE 5'-METHYLENEDIPHOSPHATE | 4h2i | A | H118 F417 | ZN | ZINC(2+) | 4h1s | A | H220 | ZN | ZINC(2+) | 4h1s | B | H220 | ZN | ZINC(2+) | 4h1y | P | H220 | ZN | ZINC(2+) | 4h2b | A | H220 | ZN | ZINC(2+) | 4h2f | A | H220 | ZN | ZINC(2+) | 4h2g | A | H220 | ZN | ZINC(2+) | 4h2i | A | H220 | CA | CALCIUM(2+) | 4h2f | A | K214 D237 G298 | CA | CALCIUM(2+) | 4h2g | A | K214 D237 G298 |
| Top |
| Conservation information for LBS of NT5E |
| Multiple alignments for P21589 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |